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TCT-345
Impact of the Novel Mobile Telemedicine System in Real- time Transmission of
Prehospital 12-lead ECG for ST-segment Elevation Acute myocardial infarction
Nobuhtio Yagi, Takafumi Yamane, Taichi Adachi, Toshikazu Jinnai, Eiji Tada,
Yoichiro Kasahara, Junichi Kotani, Hiroki Sakamoto, Hiroyuki Yokoyama, Hiroshi
Nonogi
Cardiovascular medicine, National Cerebral and Cardiovascular Center, Suita city,
Japan
Background: AHA/ACC guidelines recommend prehospital 12-lead ECG for patients
with acute coronary syndromes.However, transmission of prehospital 12-lead ECG to
emergency department (ED) is still not spread and ECG interpretation on the
prehospital and ED is not established. Therefore, we previousely reported the
usefulness of the mobile telemedicine system (MTS) to transmit 12-lead ECG and
other parameters between moving ambulances and physicians in cardiac emergency.
Methods: We set up the MTS on an ambulance in clinical condition. Real time 12-
lead ECG was transmitted together with vital signs and live video during transferring
the patient by the ambulance. We assess the efficacy and usefulness of the MTS for
the triage on 301 cardiovascular emergency cases from June 2008 to May 2011. During
the same period, we had 441 ST-segment elevation myocardial infarction (STEMI)
cases. 50 of these were used this MTS. Then, we compared various data between MTS
(n=50) and non-MTS (n=391) groups with STEMI patients.
Results: We applied the MTS for 301 patients during the transfer to our ED. The mean
time of using this MTS was 14±8 minutes. Of these, there were 84 patients (28%) with
ACS [including 50 STEMI, 6 Non-STEMI, 26 unstable angina, and 2 recent MI] Real-
time 12-lead ECGs were checked in clinical condition and all of them were comparable
to those original ECGs in the ambulance and were useful for the triage to diagnose all
AMI patients before arrival at hospital and for the rapid activation of catheterization
laboratory. Door to balloon time (DBT) was shorter in MTS group (median 82 minutes)
compared with non-MTS group (median 110 minutes) (p<0.001).
Conclusion: Accurate real-time 12-lead ECG transfer is useful for early diagnosis and
the improvement in DBT for STEMI patients.
TCT-346
ROUTINE ANGIOPLASTY AFTER FIBRINOLYTIC THERAPY FOR ST-
SEGMENT ELEVATION MYOCARDIAL INFARCTION: AN UPDATED
META-ANALYSIS (RAFT-STEMI)
Jose Donato Acuña Magno, Jean D Alcover, Angelo Dave C Javier, Felix Eduardo R
Punzalan
Section of Cardiology, Philippine General Hospital, Manila, Philippines
Background: The usefulness of a routine invasive strategy has not yet been fully
established among patients with ST-segment elevation myocardial infarction (STEMI)
who have initially been treated with fibrinolytic therapy, despite results of previous
meta-analyses. We conducted this meta-analysis to include newer and larger trials to
determine whether routine percutaneous coronary intervention (PCI) after fibrinolysis
is more beneficial than ischemia-guided PCI in reducing all-cause mortality and
reinfarction while being comparably safe in terms of stroke and major inhospital
bleeding.
Methods: Using the keywords angioplasty, stent, percutaneous coronary intervention,
fibrinolysis, thrombolysis, and myocardial infarction, we included randomized trials
on STEMI patients with >50% stent use. Outcomes included all-cause mortality,
reinfarction, stroke and in-hospital major bleeding. A routine invasive strategy referred
to PCI performed after initial fibrinolysis regardless of clinical course while an
ischemia-guided PCI management referred to PCI only if the post-fibrinolytic period
showed evidence of ischemia.
Results: We identified 7 PCI trials that enrolled 2,560 STEMI patients followed up
from 30 days to 1 year. A routine invasive strategy did not lead to significant reduction
in mortality (relative risk [RR] 0.79, 95% CI 0.56-1.11; P=0.18) but showed a
significant reduction in reinfarction (RR 0.55, 95% CI 0.40-0.77; P=0.0004) compared
with ischemia-guided management. Meanwhile, there were no significant differences
in the risk of stroke (RR 0.96, 95% CI 0.40-2.30; P=0.92) or major bleeding (RR 0.98,
95% CI 0.70-1.36; P=0.89).
Conclusion: Routine PCI after fibrinolytic therapy for STEMI patients does not
significantly reduce mortality but may be considered for its reinfarction benefit, without
increasing stroke or major bleeding. More importantly, an ischemia guided strategy is
acceptable and still relevant in the management of STEMI patients, especially in
situations where catheterization technology is not readily accessible.
TCT-347
The impact of symptom-to-door time and door-to-balloon time on 12-month
mortality in patients undergoing primary percutaneous coronary interventions
for ST-segment elevation myocardial infarction
Jang Hoon Lee1, Won Suk Choi1, Kyun Hee Kim1, Sun Hee Park1, Myung Hwan
Bae1, Dong Heon Yang1, Hun Sik Park1, Yongkeun Cho1, Shung Chull Chae1, Jae
Eun Jun1, Myung Ho Jeong2, Young Jo Kim3
1Kyungpook National University Hospital, Daegu, Republic of Korea; 2Chonnam
National University Hospital, Gwangju, Republic of Korea; 3Yeungnam University
Hospital, Daegu, Republic of Korea
Background: The aims of this study were to determine the interactive effect of
symptom-to-door (STD) time and door-to-balloon (DTB) time on 12-month mortality
in patients undergoing primary percutaneous coronary interventions (PCI) for ST-
segment elevation myocardial infarction (STEMI).
Methods: Between November 2005 and January 2008, 3,108 eligible patients (2,307
men; mean age = 61.8 ± 12.6 years-old) who had an STEMI with an STD time less
than 12 hours and underwent primary PCI were analyzed from the Korea Acute MI
Registry. Patients were stratified into 4 groups based on STD time (<3 versus ≥3 hours)
and DTB time (<90 versus ≥90 minutes). The cutoff points of 3 hours for STD time
and 90 minutes for DTB time were chosen after preliminary analyses of the relation
between STD time and mortality and DTB time and mortality.
Results: The patients with a STD time of <3 hours and DTB time of <90 minutes had
the lowest 12-month mortality (5.9%). Patients with a STD time of <3 hours and DTB
time ≥90 minutes and had significantly greater mortality than patients with an STD
time of <3 hours and DTB time of <90 minutes (hazard ratio [HR] 1.866, 95%
confidence interval [CI] 1.010 to 3.447, p=0.046), as did patients with a STD time of
≥3 hours and DTB time of <90 minutes (adjusted HR 1.957, 95% CI 1.040 to 3.681,
p=0.037) after adjustment for clinical and angiographic variables in Cox proportional
hazards model. The patients with a STD time of ≥3 hours and DTB time of ≥90 minutes
had the highest 12-month mortality compared to patients with an STD time of <3 hours
and DTB time of <90 minutes after adjustment for clinical and angiographic variables
(adjusted HR 2.554, 95% CI 1.388 to 4.700, p=0.003), and after adjustment for clinical,
angiographic, and discharge medications (adjusted HR 2.217, 95% CI 1.015 to 4.843,
p=0.046).
Conclusion: This observational study suggest the combination of short (<3 hours)
OTD time short (<90 minutes) DTB time are associated with the lowest 12-month
mortality in patients with STEMI.
TCT-348
Temporal Trends in Treatment and Outcomes of Patients with ST-Segment
Elevation Myocardial Infarction in Clinical Practice - Analysis from the PL-
ACS Registry
Lech Polonski1, Mariusz Gasior1, Marek Gierlotka1, Pawel Buszman2, 1, Witold
Ruzyllo3, Jacek Dubiel4, Waldemar Banasiak5, Zbigniew Kalarus1, Marian Zembala1,
Grzegorz Opolski6
1Silesian Centre for Heart Diseases, Zabrze, Poland; 2American Heart of Poland,
Katowice, Poland; 3Institute of Cardiology, Warsaw, Poland; 4Jagiellonian
University Medical College, Krakow, Poland; 54th Military Hospital, Wroclaw,
Poland; 6Medical University, Warsaw, Poland
Background: Management of patients with non-ST-segment elevation myocardial
infarction (STEMI) differs between countries and a gap still exists between guidelines
and current clinical practice. These differences are also observed with time. Therefore
we analyzed temporal trends in treatment and outcomes of STEMI patients in Poland.
Methods: All patients with STEMI (N = 82135), who were registered in the
prospective Polish Registry of Acute Coronary Syndromes from 2004 to 2009 in 452
hospitals scattered throughout Poland were included. Follow-up mortality was obtained
from the government database.
Results: Mean age was stable during 6 years. Significant increase was observed in
percentage of STEMI patients receiving guidelines’ recommended treatment, both
pharmacological and invasive. Median length of stay was significantly has shorter in
2009 compared to 2004. As patients were more aggressively treated (rise reperfusion
therapy) with time, the rates of PCI raised, the rates of thrombolysis declined, and early
as well as 12-month mortality significantly decreased in the subsequent years. Of note
is the increase in major bleedings.
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Conclusion: Increase in adherence to the guidelines leads to decrease in short and mid-
term mortality in STEMI, but the increase in major bleeding complications was noted.
TCT-349
Monocyte Platelet Aggregate act as Platelet Function Assay and Prognostic
Marker for Acute Myocardial Infarction
Ho Lam1, Chiu Kam Chan2, Sze Fai Yip2, Ping Wa Yam1, Ka Lung Chui1, Yu Ho
Chan1, Kowk Kit Yeung1, Yam Hong Wong1, Wai Keung Lai1, Liang Chow1
1Department of Medicine and Geriatrics, Tuen Mun Hospital, Tuen Mun, Hong
Kong; 2Department of Clinical Pathology, Tuen Mun Hospital, Tuen Mun, Hong
Kong
Background: During acute myocardial infarction (AMI), degranulated platelets adhere
to the monocytes and form monocyte platelet aggregate (MPA). The level of MPA can
therefore reflect the pathological change and indicate the degree of inflammation and
thrombosis in AMI. Recently, MPA assay has been developed for in vivo platelet
function assessment. MPA may act as a biomarker for ACS.
Methods: In this single-center prospective observational study, we recruited 29
consecutive AMI patients and 19 healthy controls. Blood samples in first 24 hrs of
AMI and Day 5 after dual antiplatelet treatment were taken from patients. MPA level
was measured by flow cytometry. MPA in circulating blood were displayed in a dual-
fluorescence dot plot of CD14-FITC and CD41-PE. MPA level of the health subjects
and AMI patients were compared. In wave one analysis, patients were grouped into
high MPA group and low MPA group by upper limit of the normal subjects, in which
baseline characteristics and clinical endpoints between two groups were compared. In
wave two analysis, patients with rising trend of MPA after dual antiplatelet treatment
and patients with decreasing trend of MPA were compared. The endpoint is composite
cardiovascular endpoints of death, recurrent ACS, cardiogenic shock, heart failure and
ventricular tachycardia/ventricular fibrillation (VT/VF) in post AMI day 30.
Results: MPA level in AMI patients (mean= 33) are significantly higher than the
normal health subjects (mean=25). (p<0.05). In wave one analysis, high MPA group
(n=9) and low MPA (n=20) group reaching the endpoint were 55% (n=5) and 30%
(n=6) respectively. (p=0.2). In wave two analysis, rising MPA group (n= 12) showed
58.3 % (n=7) patients reaching endpoint. Decreasing trend MPA group (n=9) showed
11.1% (n=1) patient reaching endpoint. Rising MPA group showed a trend of more
post MI complications compared to decreasing MPA group but statistically, it is not
significant. (p= 0.06).
Conclusion: MPA significantly elevated in AMI patients. There is a trend that high
MPA and rising MPA in AMI patients will have more post MI complications.
TCT-350
Very Late Hazard with Primary Stenting versus Primary PTCA for STEMI: A
16 Year Single Center Experience
Bruce R Brodie1, Yashashwi Pokharel2, Ankit Garg2, Charles Hansen2, Sally Milks1,
Michael Cooper1, Christopher McAlhany1, Thomas Stuckey1
1Cone Heart and Vascular Center, Greensboro, NC; 2University of North Carolina
Internal Medicine Residency Program, Greensboro, NC
Background: Stenting compared with PTCA for STEMI reduces TVR and target
vessel re-occlusion at 6-12 months. Comparison of outcomes beyond 12 months has
not been studied. We hypothesized that there may be a very late hazard with stenting
vs PTCA due to very late stent thrombosis (ST).
Methods: From 1995-2010 consecutive pts with STEMI were treated with primary
PTCA (n=601) or primary stenting with BMS or DES (n=1594). Clinical and
angiographic follow-up were obtained at 1-16 yrs. Comparable definitions were used
for ST (ARC definite or probable) and lesion thrombosis (LT).
Results: Pts treated with PTCA were older, more often female, had more hypertension,
more 3V CAD, smaller vessels, more TIMI 0-1 flow at initial angiography, and longer
reperfusion times. At 1 yr there were mild trends for lower mortality, MI and ST/LT
with stenting vs PTCA. In landmark analyses after 1 yr, pts treated with stenting vs
PTCA had more very late ST/LT (Figure) and more TV MI but no differences in death
or total MI. Most of the differences in ST/LT and TV MI between stents and PTCA
were due to differences between DES and PTCA with smaller differences between
BMS and PTCA. After adjusting for baseline risk, stents vs PTCA had more very late
ST/LT (HR 2.63, 95% CI 1.40-4.95, p=0.003) and more very late TV MI (HR 2.98,
95% CI 1.68-5.31, p<0.001).
Conclusion: There appears to be a very late hazard with primary stenting compared
with primary PTCA for STEMI with more very late ST/LT and more TV MI. These
data should encourage new strategies for prevention of very late ST with both BMS
and DES including the development of bio-absorbable stents and polymers.
TCT-351
Impact of Bleeding on Mortality in Patients Referred for Primary PCI
Michel Le May, Derek So, Chris Glover, Michael Froeschl, Alexander Dick, Jean-
Francois Marquis, Edward O’Brien, George Wells, Melissa Blondeau, Li Chen,
Marino Labinaz
University of Ottawa Heart Institute, Ottawa, Canada
Background: There is limited contemporary data on factors that predict bleeding in
the setting of primary PCI, and on the impact of bleeding on mortality.
Methods: We identified pts referred for primary PCI from our database. Standard
therapy before catheterization included ASA 160mg, clopidogrel 600mg and UFH 60
u/kg (max 4000). Bleeding was defined as TIMI major/minor bleeding. We used
logistic regression to determine baseline variables associated with bleeding during the
initial hospitalization and all-cause mortality at 180 days.
Results: Between May 2005 and July 2010, 2032 consecutive pts with STEMI were
referred for primary PCI. Primary PCI was performed in 93% of pts and transradial
access was used in 12%. Bivalirudin was used in to 29% of pts and glycoprotein 2b/3a
inhibitors to 36%. Bypass surgery was performed in 4%. TIMI major/minor bleeding
occurred in 14.8% of pts: TIMI major in 4.5% and TIMI minor in 10.3%. Blood
transfusion was needed in 6.3% of pts. Independent predictors of bleeding were Killip
class, anterior STEMI, transfemoral access, age, anemia, serum creatinine, door-to-
balloon time, height and the use of glycoprotein 2b/3a vs. bivalirudin. Mortality at 180
days was 7.7% for the entire group: 18.5% in pts with bleeding vs. 5.6% in pts without
bleeding, p<0.0001. The mortality rate was 24.4% in pts with major bleeding and
15.8% in pts with minor bleeding. The results of the multivariable analysis to determine
predictors of mortality at 180 days are shown in the Table below.
Conclusion: In the real world setting, TIMI major and TIMI minor bleeding are
important predictors of mortality in pts referred for primary PCI. Altering factors that
predict bleeding could lead better clinical outcomes.
TCT-352
Prior Coronary Artery Bypass Graft (CABG) Patients Treated with Primary
Percutaneous Coronary Intervention (PPCI) Have Higher Long-Term Major
Adverse Cardiovascular Event (MACE) Rates
Mohammed Majid Akhtar, Daniel A Jones, Krishna S Rathod, Adam Graham, O.
Guttmann, S. Gallagher, Ajay Jain, Charles Knight, Anthony Mathur, Andrew Wragg
Cardiology, Barts & The London Hospitals NHS Trust, Hornchurch, United
Kingdom
Background: Limited information exists regarding procedural success and clinical
outcomes of patients with prior CABG undergoing PPCI for STEMI. We sought to
compare outcomes in this group.
Methods: Data was analysed from a prospective database on 2322 STEMI patients
undergoing PPCI between 2004-2010 at a London centre. 104 of 2,322 (4.5%) patients
had prior CABG. Information was entered at the time of procedure and outcome
assessed by all-cause mortality information.
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